Alicia Grande - Mar 22, 2023 Form 4 Insider Report for CATALYST PHARMACEUTICALS, INC. (CPRX)

Role
VP, Treasurer and CFO
Signature
/s/ Alicia Grande
Stock symbol
CPRX
Transactions as of
Mar 22, 2023
Transactions value $
-$656,518
Form type
4
Date filed
3/24/2023, 05:00 PM
Previous filing
Feb 17, 2023
Next filing
Mar 30, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CPRX Common stock, par value $0.001 per share Options Exercise $2.58K +3.26K +6.45% $0.79* 53.8K Mar 22, 2023 Direct
transaction CPRX Common stock, par value $0.001 per share Sale -$53.5K -3.26K -6.06% $16.41 50.6K Mar 22, 2023 Direct F1, F3
transaction CPRX Common stock, par value $0.001 per share Options Exercise $30.4K +38.5K +76.2% $0.79* 89.1K Mar 22, 2023 Direct
transaction CPRX Common stock, par value $0.001 per share Sale -$636K -38.5K -43.25% $16.51 50.6K Mar 22, 2023 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CPRX Options to purchase common stock Options Exercise $0 -3.26K -0.23% $0.00 1.44M Mar 22, 2023 Common Stock 3.26K $0.79 Direct F4
transaction CPRX Options to purchase common stock Options Exercise $0 -38.5K -2.67% $0.00 1.4M Mar 22, 2023 Common Stock 38.5K $0.79 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares were sold in various lots from $16.40 to $16.425 per share. The listed sale price represents a weighted average price for the shares sold.
F2 Shares were sold in various lots from $16.50 to $16.555 per share. The listed sale price represents a weighted average price for the shares sold.
F3 Shares were sold to cover exercise price of options, tax withholding requirements and for personal reasons. Shares were not sold as a result of any disagreement with the Company and Ms. Grande remains an officer of the Company.
F4 Options vested in two annual tranches beginning on June 15, 2017.